1,489 results on '"de Stanchina, Elisa"'
Search Results
2. Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferation
3. Correction: SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing
4. SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing
5. CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation
6. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma
7. Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification
8. TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models
9. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
10. Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance
11. ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1
12. Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma
13. Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers
14. Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models
15. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
16. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance
17. Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies
18. Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer
19. Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
20. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma
21. Cooperative CAR targeting to selectively eliminate AML and minimize escape
22. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification
23. PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis.
24. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade
25. Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
26. Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia
27. Rapid interrogation of cancer cell of origin through CRISPR editing
28. Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts
29. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma
30. Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library
31. ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance
32. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors
33. uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence.
34. eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer
35. Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation
36. MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer
37. ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
38. Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers
39. Functional Genomics In Vivo Reveal Metabolic Dependencies of Pancreatic Cancer Cells
40. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy
41. Preclinical Evaluation of Chimeric Antigen Receptor-Modified Natural Killer Cells Targeting Membrane-Proximal CD33 in Acute Myelogenous Leukemia
42. Abstract B089: Oncogenic signaling and responses to treatment in RAS mutant cancers are mutation-specific
43. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
44. NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
45. Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation
46. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
47. Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
48. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
49. The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing
50. Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.